A5001637416- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Neuroendocrine Tumor Research Advances
- Lung Cancer Treatments and Mutations
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer, Lipids, and Metabolism
- Gastric Cancer Management and Outcomes
- Inflammatory Biomarkers in Disease Prognosis
- Liver Disease Diagnosis and Treatment
- Lung Cancer Research Studies
- PI3K/AKT/mTOR signaling in cancer
- Monoclonal and Polyclonal Antibodies Research
- Genetic factors in colorectal cancer
- Cancer, Hypoxia, and Metabolism
- CAR-T cell therapy research
- Cancer Mechanisms and Therapy
- Cancer-related Molecular Pathways
- Cancer therapeutics and mechanisms
- Hepatitis C virus research
- Multiple and Secondary Primary Cancers
- Multiple Myeloma Research and Treatments
- Virus-based gene therapy research
Montefiore Medical Center
2016-2025
Albert Einstein College of Medicine
2016-2025
Jacobi Medical Center
2024
Montefiore Einstein Comprehensive Cancer Center
2004-2024
University of Oxford
2017
Princess Margaret Cancer Centre
2012-2014
Moffitt Cancer Center
2012-2014
Memorial Sloan Kettering Cancer Center
2000-2014
Mayo Clinic in Arizona
2014
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
2012
Normal bone marrow cells have little or no expression of the MDR p-glycoprotein product and, therefore, are particularly susceptible to killing by MDR-sensitive drugs, such as vinca alkaloids, anthracyclines, podophyllins, and paclitaxel its congeners. Here we report results a phase I clinical trial that tested safety efficacy transfer human multiple drug resistance (MDR1, MDR) gene into hematopoietic stem progenitors in means providing these toxic effects cancer chemotherapy.Up one third...
The nuclear receptor pregnane X (PXR) is activated by a range of xenochemicals, including chemotherapeutic drugs, and has been suggested to play role in the development tumor cell resistance anticancer drugs. PXR also implicated as regulator growth apoptosis colon tumors. Here, we have used xenograft model cancer define molecular mechanism that might underlie PXR-driven malignancy. Activation was found be sufficient enhance neoplastic characteristics, growth, invasion, metastasis, both human...
Purpose There are few effective therapies for pancreatic neuroendocrine tumors (PNETs). Recent placebo-controlled phase III trials of the mammalian target rapamycin (mTOR) inhibitor everolimus and vascular endothelial growth factor (VEGF)/platelet-derived receptor sunitinib have noted improved progression-free survival (PFS). Preclinical studies suggested enhanced antitumor effects with combined mTOR VEGF pathway–targeted therapy. We conducted a clinical trial to evaluate combination therapy...
Pexastimogene devacirepvec (Pexa-Vec) is a vaccinia virus-based oncolytic immunotherapy designed to preferentially replicate in and destroy tumor cells while stimulating anti-tumor immunity by expressing GM-CSF. An earlier randomized Phase IIa trial predominantly sorafenib-naïve hepatocellular carcinoma (HCC) demonstrated an overall survival (OS) benefit. This randomized, open-label IIb investigated whether Pexa-Vec plus Best Supportive Care (BSC) improved OS over BSC alone HCC patients who...
Previous communication has reported significant improvement in overall survival (OS) when using doxorubicin plus sorafenib the treatment of advanced hepatocellular cancer (HCC).To determine if added to therapy improves OS, with stratification for locally and metastatic disease.This unblinded randomized phase 3 clinical trial was led by Alliance collaboration Eastern Cooperative Oncology Group-American College Radiology Imaging Network, Canadian Cancer Trials Group, Southwest Group. It...
192 Background: An exploratory analysis of a randomized phase II study in HCC comparing doxorubicin (D) alone to plus sorafenib (D+S) showed significant improvement overall survival favoring D+S (JAMA, 2011). The results appeared promising compared the historic outcomes seen pivotal (S) trials. CALGB 80802 was designed determine if improved S alone. Methods: Patients with histologically proven advanced HCC, no prior systemic therapy and Child-Pugh A were receive D 60 mg/m 2 every 21 days 400...
PURPOSE SHR-A1811 is an antibody-drug conjugate composed of anti–human epidermal growth factor receptor 2 (HER2) antibody trastuzumab, a cleavable linker, and topoisomerase I inhibitor payload. We assessed the safety, tolerability, antitumor activity, pharmacokinetics in heavily pretreated HER2-expressing or mutated advanced solid tumors. METHODS This global, multi-center, first-in-human, phase trial was conducted at 33 centers. Patients who had unresectable, advanced, metastatic tumors were...
We have induced fresh peripheral blood K/natural killer cells to lyse a variety of target by coating them with anti-Fc gamma receptor (anti-Fc R) (CD16) antibody hetero-cross-linked anti-target cell antibody. The cytotoxic mediating this activity is different, as judged depletion studies, from the CD3+, CD8+ T which targeted anti-CD3 cross-linked Targeted K some donors enhanced exposure interleukin 2 but not interferon-gamma; other exhibit high amounts without stimulation. Specificity lysis...
Purpose Preclinical studies indicate that the cyclin-dependent kinase and protein C inhibitor 7-hydroxystaurosporine (UCN-01) potentiates cytotoxic effects of fluorouracil (FU). We designed a phase I clinical trial FU in combination with UCN-01. Patients Methods was administered as weekly 24-hour infusion. Doses were escalated successive cohorts according to modified Fibonacci design. UCN-01 once every 4 weeks, immediately after disconnection from FU, at dose 135 mg/m 2 over 72 hours cycle 1...
Background: : Incidence of hepatocellular cancer (HCC) in the Bronx is 61% higher than rest New York State. Underserved populations are not well represented clinical trials immune checkpoint inhibitors (ICI). Methods: Demographics were tabulated for 194 patients treated with ICI at Montefiore-Einstein Comprehensive Cancer Center (MECCC) between 2017 and 2022. Categorical variables analyzed by Chi-squared test, survival was using Kaplan–Meier (KM) curves. Results: MECCC 40.7% Hispanic 20.6%...
671 Background: Neuroendocrine tumors (NETs) pose different clinical implications based upon age at diagnosis, with regards to early-onset (EO<50yrs) versus late-onset (LO>=50yrs) disease. While primary-tumor resection is crucial for localized NETs, its benefit in metastatic cases without metastasectomy remains uncertain. This study examines variables associated survival EO LO cases, including primary tumor resection. Methods: A retrospective cohort of 91 patients...
105 Background: Despite the declining incidence rates (IR) in average onset colon cancer (AO-CC), IR for early (EO-CC), defined as patients (pts) younger than 50-years-old at diagnosis, has been increasing. Treatment high risk locally advanced (CC) is surgical resection followed by adjuvant chemotherapy (AC). Data indicates a more permissive use EO-CC. There limited data about treatment and survival trends Thus, we aimed to assess benefit of AC between EO vs AO CC disease. Methods: diagnosed...
The binding of protein antigens to APC with heterocrosslinked bispecific antibodies (HBAs) enhances their processing and presentation Th cells in vitro. Here we have asked whether HBAs could also increase immune responses vivo. We immunized mice hen egg lysozyme (HEL) the presence or absence HBA, followed antibody production after primary challenge a secondary boost. found that bind antigen MHC class I II molecules, Fc gamma R, but not surface IgD, enhance immunogenicity HEL. bound HEL for...
To determine the efficacy and toxicity of protein kinase C inhibitor bryostatin-1 plus paclitaxel in patients with advanced pancreatic carcinoma.Each treatment cycle consisted 90 mg/m by intravenous infusion over 1 hour on days 1, 8, 16, bryostatin 25 mcg/m as a 1-hour 2, 9, 15, given every 28 days. Patients were evaluated for response after 2 cycles, continued therapy until disease progression or prohibitive toxicity. The primary objective was to whether combination produced rate at least...
4003 Background: An exploratory analysis of a randomized phase II study in HCC comparing doxorubicin (D) alone to plus sorafenib (D+S) showed significant improvement overall survival favoring D+S (JAMA, 2011). The results appeared promising compared the historic outcomes seen pivotal (S) trials. CALGB 80802 was designed determine if improved S alone. Methods: Patients with histologically proven advanced HCC, no prior systemic therapy and Child-Pugh A were receive D 60 mg/m2 every 21 days 400...
Background: Orthotopic liver transplantation (OLT) is the most effective treatment for hepatocellular carcinoma (HCC) in patients with underlying cirrhosis and portal hypertension. Availability of OLT limited by donor-organ shortages, which increase patient waiting time until OLT. A variety bridging therapies (BT) have been used to halt tumor progression on list. Despite complete radiologic responses following BT, viable often present explants. Methods: Treatment outcomes were evaluated 50...
Purpose: To assess the activity and toxicity of lenalidomide for patients with advanced hepatocellular cancer (HCC) previously treated sorafenib. Materials Methods: Patients HCC who progressed on or were intolerant to sorafenib eligible. received 25 mg orally 1 21 days in a 28-day cycle until disease progression unacceptable toxicities. Results: Forty enrolled classified according Child-Pugh score: 19 A, 16 B, 5 C. Seventeen had extrahepatic disease. Grade 4 neutropenia occurred 40 (2.5%). 3...